Archive for the ‘Glomerulonephritis’ Category

April 1, 2013

Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.

.   .   

This small retrospective study analyzed the efficacy and safety of rituximab in adults with steroid-dependent minimal change disease. Of the seventeen relapsing steroid-dependent patients treated with rituximab, eleven had no relapses with nine being able to come off all other drugs during the mean 29.5 month follow-up period. This sets the stage for a prospective […]

Comments Off on Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Posted in Clinical Nephrology, Glomerulonephritis
April 1, 2013

Expert guidelines for the management of alport syndrome and thin basement membrane nephropathy.

.   .   

This review article provides an expert look at the diagnosis and management of alport syndrome and thin basement membrane nephropathy.

Comments Off on Expert guidelines for the management of alport syndrome and thin basement membrane nephropathy. Posted in Clinical Nephrology, Clinical Practice Guidelines, Glomerulonephritis
January 28, 2013

Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?

.   .   

The side-effect profile of cyclophosphamide is well-known and most clinicians only prescribe it in the most severe disease. This review compares cyclophosphamide to mycophenolate mofetil for induction and maintenance therapy for severe lupus nephritis. Using the available evidence, the authors conclude that mycophenolate mofetil is a viable alternative for therapy, although cyclophosphamide may have a […]

Comments Off on Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Posted in Glomerulonephritis, Review
May 23, 2012

KDIGO Clinical Practice Guideline for Glomerulonephritis

These extensive guidelines provide guidance of the management of both pediatric and adult patients with glomerulonephritis.

Comments Off on KDIGO Clinical Practice Guideline for Glomerulonephritis Posted in Clinical Practice Guidelines, Glomerulonephritis
April 5, 2012

Membranoproliferative Glomerulonephritis — A New Look at an Old Entity

.   .   

MPGN accounts for approximately 10% of cases of glomerulonephritis.  This article nicely reviews the causes, pathogenesis and clinical management.

Comments Off on Membranoproliferative Glomerulonephritis — A New Look at an Old Entity Posted in Glomerulonephritis, Review
January 28, 2012

Focal Segmental Glomerulosclerosis

.   .   

FSGS accounts for appoximately 40% of adult nephrotic syndrome.  This review provides an approaches to the diagnosis and management of this disease.

Comments Off on Focal Segmental Glomerulosclerosis Posted in Glomerulonephritis, Review
November 29, 2011

Current Therapy for IgA Nephropathy

.   .   

IgA nephropathy is a multi-faceted disease with many clinical presentations that are not always easy to manage.  This review nicely summarizes the therapeutic options using four clinical scenarios of patients with IgA nephropathy. Free full text kindly provided by the American Society of Nephrology

Comments Off on Current Therapy for IgA Nephropathy Posted in Glomerulonephritis
November 12, 2011

Late Breaking Clinical Trials at ASN 2011 – FISH study and more

The late breaking clinical trials session from the 2011 American Society of Nephrology meeting was held on November 12, 2011.  The following are summaries of some of the clinical trial results.  Access to the full details of these studies awaits publication in peer reviewed journals. Charmaine E. Lok et al.  The Fish Oil Inhibition of Stenosis […]

Comments Off on Late Breaking Clinical Trials at ASN 2011 – FISH study and more Posted in Bone Mineral Metabolism, Clinical Trial Results, General Nephrology, Glomerulonephritis, Pediatric Nephrology, Renal Transplantation, Vascular Access
October 8, 2011

Podocyte disorders: core curriculum 2011

.   .   

This paper provides point form review of normal and pathological glomerular function, as well as major types of podocyte disorders including minimal change disease, membranous nephropathy and FSGS.

Comments Off on Podocyte disorders: core curriculum 2011 Posted in AJKD Core Curriculum, Glomerulonephritis
October 8, 2011

Persistent Asymptomatic Isolated Microscopic Hematuria in Israeli Adolescents and Young Adults and Risk for End-Stage Renal Disease

.   .   

This study linked an ESRD registry to retrospective medical data for persons aged 16-25 examined for military fitness.  It showed that persistent asymptomatic microscopic hematuria was associated with an increased risk of ESRD, with an adjusted hazard ratio of 18.5 [95% CI, 12.4-27.6].  While the absolute risk of ESRD in patients with microscopic hematuria remains […]

Comments Off on Persistent Asymptomatic Isolated Microscopic Hematuria in Israeli Adolescents and Young Adults and Risk for End-Stage Renal Disease Posted in Chronic Kidney Disease, Glomerulonephritis
February 8, 2011

Posttransplant Recurrence of Primary Glomerulonephritis

.   .   

As the incidence of graft loss due to acute rejection decreases, recurrence of glomerulonephritis post-transplant has become more common. This review covers the incidence, mechanisms and treatment of four types of primary glomerulonephritis: IgA nephropathy, focal segmental glomerulosclerosis, membranous nephropathy and membranoproliferative glomerulonephritis. Full text kindly provided by the American Society of Nephrology.

Comments Off on Posttransplant Recurrence of Primary Glomerulonephritis Posted in Glomerulonephritis, Renal Transplantation
January 11, 2010

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

.   .   

Results of two randomized trial using induction treatment with either MMF or intravenous cyclophosphamide were pooled in this article. At 24 weeks, the results show that both groups were similar with respect to percentage change in proteinuria and serum creatinine as end points when used to treat patients with class V lupus.

Comments Off on Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis Posted in Glomerulonephritis, Lupus
October 18, 2009

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.

.   .   

This meta-analysis suggests that for the treatment of proliferative lupus nephritis, MMF offers similar efficacy in renal remission and survival as cyclophosphamide with a better safety profile.

Comments Off on Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Posted in Glomerulonephritis, Lupus